We will explore the complex landscape of the Inflation Reduction Act and its profound implications on the pharmaceutical industry in this in-depth panel discussion. Experts from different facets of the industry will dissect how the IRA influences pricing structures, market access strategies, and overall business models, providing actionable insights for navigating these changes.
Experts will succinctly break down the critical aspects of the IRA affecting pharmaceutical pricing and access, including government negotiations, Medicare Part D changes, and spending caps.
Business Model Adaptations: Panelists will discuss the transformation of pharmaceutical business models under the IRA, focusing on new pricing strategies, the necessity for transparency, and innovation within fiscal limitations.
Effects on Innovation and Small Firms: The panel will examine the IRA’s potential impact on innovation, especially its effect on funding for research and development, and its implications for smaller biotech firms facing investment and regulatory challenges.
Insights will be shared on adjusting to the IRA’s evolving regulatory landscape, with emphasis on strategic planning to manage market shifts and maintain competitiveness.
Monday September 30, 2024 4:00pm - 4:45pm EDT
Log in to save this to your schedule, view media, leave feedback and see who's attending!
